Möhring, C.; Berger, M.; Sadeghlar, F.; Zhou, X.; Zhou, T.; Monin, M.B.; Shmanko, K.; Welland, S.; Sinner, F.; Schwacha-Eipper, B.;
et al. Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study. Cancers 2025, 17, 972.
https://doi.org/10.3390/cancers17060972
AMA Style
Möhring C, Berger M, Sadeghlar F, Zhou X, Zhou T, Monin MB, Shmanko K, Welland S, Sinner F, Schwacha-Eipper B,
et al. Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study. Cancers. 2025; 17(6):972.
https://doi.org/10.3390/cancers17060972
Chicago/Turabian Style
Möhring, Christian, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Malte Benedikt Monin, Kateryna Shmanko, Sabrina Welland, Friedrich Sinner, Birgit Schwacha-Eipper,
and et al. 2025. "Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study" Cancers 17, no. 6: 972.
https://doi.org/10.3390/cancers17060972
APA Style
Möhring, C., Berger, M., Sadeghlar, F., Zhou, X., Zhou, T., Monin, M. B., Shmanko, K., Welland, S., Sinner, F., Schwacha-Eipper, B., Bauer, U., Roderburg, C., Pirozzi, A., Ben Khaled, N., Schrammen, P., Balcar, L., Pinter, M., Ettrich, T. J., Saborowski, A.,
... Gonzalez-Carmona, M. A.
(2025). Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study. Cancers, 17(6), 972.
https://doi.org/10.3390/cancers17060972
